Literature DB >> 12415062

Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.

Elke Lainka1, Selda Oezbek, Manfred Falck, Jennifer Ndagijimana, Tim Niehues.   

Abstract

OBJECTIVE: To assess the effects of antiretroviral combination therapy that contains protease inhibitor (PI) on carbohydrate and lipid metabolism in human immunodeficiency virus (HIV)-infected children.
METHODS: A cross-sectional, descriptive clinical study was conducted in an outpatient clinic. Thirty-seven HIV-infected children who ranged from 1 to 17 years of age received nucleoside reverse transcriptase inhibitor treatment together with PI (PI group, n = 25) or without PI (non-PI group, n = 12). Age, gender, weight, length, CD4 cell count, and viral load did not differ between groups. Nonfasting total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein (LDL) cholesterol, glucose, lactate, and blood gases were determined. In addition, c-peptide, insulin, hemoglobin A1c, free fatty acids, lipoprotein a, and apolipoproteins A1 and B were evaluated after fasting. PI and non-PI group values were compared with normal values taken from healthy children.
RESULTS: In nonfasting and fasting conditions, children of the PI group had higher total cholesterol (fasting PI group: 235 +/- 71 mg/dL; non-PI group: 176 +/- 25 mg/dL, mean +/- standard deviation), triglycerides (156 +/- 89 vs 87 +/- 31 mg/dL), and LDL cholesterol levels (159 +/- 58 vs 113 +/- 23 mg/dL) compared with the non-PI group. High-density lipoprotein cholesterol and apolipoprotein A1 levels did not differ in both groups; there was a trend toward higher apolipoprotein B levels in the PI group. After fasting, 8 (47%) of 17 patients in the PI group presented with hypercholesterolemia as a result of an increase of LDL cholesterol and 11 (65%) had hypertriglyceridemia. It is interesting that the non-PI group showed no pathologic deviations. Compared with normal values, lipoprotein a and free fatty acids were increased in the PI and non-PI groups. Glucose, lactate, blood gases, c-peptide, insulin, and hemoglobin A1c were normal in both groups.
CONCLUSION: PI-containing antiretroviral treatment of HIV-infected children was associated with hypercholesterolemia, hypertriglyceridemia, and an increase of LDL cholesterol. The long-term complications of dyslipidemia are of major concern in the growing HIV-infected child.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12415062     DOI: 10.1542/peds.110.5.e56

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  17 in total

1.  Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study.

Authors:  Luminita Ene; Tessa Goetghebuer; Marc Hainaut; Alexandra Peltier; Véronique Toppet; Jack Levy
Journal:  Eur J Pediatr       Date:  2006-07-29       Impact factor: 3.183

2.  Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.

Authors:  Ann J Melvin; Grace Montepiedra; Lisa Aaron; William A Meyer; Hans M Spiegel; William Borkowsky; Mark J Abzug; Brookie M Best; Marilyn J Crain; Peggy R Borum; Bobbie Graham; Patricia Anthony; Katherine Shin; George K Siberry
Journal:  Pediatr Infect Dis J       Date:  2017-01       Impact factor: 2.129

3.  Clinical management and follow-up of hypercholesterolemia among perinatally HIV-infected children enrolled in the PACTG 219C study.

Authors:  Denise L Jacobson; Paige Williams; Katherine Tassiopoulos; Ann Melvin; Rohan Hazra; John Farley
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-15       Impact factor: 3.731

4.  Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy.

Authors:  Renate Strehlau; Ashraf Coovadia; Elaine J Abrams; Leigh Martens; Stephen Arpadi; Tammy Meyers; Louise Kuhn
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-01       Impact factor: 3.731

5.  Alcoholic Extract of Lotus Leaves Improves Lipid Profile in Rats with HIV Protease Inhibitor-induced Dyslipidaemia.

Authors:  Q J Su; Z Z Lu; Q Y Deng; B M Wei
Journal:  West Indian Med J       Date:  2015-07-21       Impact factor: 0.171

6.  Metabolic abnormalities and coronary heart disease risk in human immunodeficiency virus-infected adults.

Authors:  Clive R Pullinger; Bradley E Aouizerat; Caryl Gay; Traci Coggins; Irina Movsesyan; Harvey Davis; John P Kane; Carmen Portillo; Kathryn A Lee
Journal:  Metab Syndr Relat Disord       Date:  2010-06       Impact factor: 1.894

7.  Dyslipidemia in a cohort of HIV-infected Latin American children receiving highly active antiretroviral therapy.

Authors:  Margaret Brewinski; Karen Megazzini; Laura Freimanis Hance; Miguel Cashat Cruz; Noris Pavia-Ruz; Marinella Della Negra; Flavia Gomes Faleiro Ferreira; Heloisa Marques; Rohan Hazra
Journal:  J Trop Pediatr       Date:  2010-10-01       Impact factor: 1.165

8.  World Health Organization generic protocol to assess drug-resistant HIV among children <18 months of age and newly diagnosed with HIV in resource-limited countries.

Authors:  Silvia Bertagnolio; Martina Penazzato; Michael R Jordan; Deborah Persaud; Lynne M Mofenson; Diane E Bennett
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

9.  Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children.

Authors:  Katherine Tassiopoulos; Paige L Williams; George R Seage; Marilyn Crain; James Oleske; John Farley
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

10.  Getting to 90-90-90 in paediatric HIV: What is needed?

Authors:  Mary-Ann Davies; Jorge Pinto; Marlène Bras
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.